Glucose Catabolism in Cancer Cells

THE TYPE II HEXOKINASE PROMOTER CONTAINS FUNCTIONALLY ACTIVE RESPONSE ELEMENTS FOR THE TUMOR SUPPRESSOR p53*

  1. Peter L. Pedersen
  1. From the Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2185

Abstract

The p53 tumor suppressor is found to be mutated and abundant in a wide variety of tumors. Within tumors showing rapid growth, the Type II isoform of hexokinase is also highly expressed to facilitate high rates of glucose catabolism, which in turn promote their rapid proliferation. We previously reported isolation of the proximal promoter of the Type II hexokinase gene from the highly glycolytic hepatoma AS-30D (Mathupala, S. P., Rempel, A., and Pedersen, P. L. (1995) J. Biol. Chem. 270, 16918–16925). Here, we show that a p53 protein, exhibiting two point mutations in its cDNA, is abundantly expressed in the AS-30D hepatoma. Co-expression studies showed that p53 overexpression significantly and reproducibly activated the Type II hexokinase promoter. Two functional p53 motifs were identified within this promoter by footprint and gel retardation analyses. Presence of functional p53 response elements on the Type II hexokinase promoter and the positive regulatory effect on the promoter by the mutant p53 indicates that in rapidly growing liver tumors, and perhaps in many other tumors as well, this highly abundant p53 protein plays a role in maintaining a high glycolytic rate. This is the first report of a possible link between loss of cell cycle control in rapidly growing cancer cells and their high glycolytic phenotype.

Footnotes

  • * This work was supported by National Institutes of Health Grant CA 32742 (to P. L. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    The nucleotide sequence(s) reported in this paper has been submitted to the GenBank™/EMBL Data Bank with accession number(s) U90328.

  • To whom correspondence should be addressed: The Johns Hopkins University School of Medicine, Dept. of Biological Chemistry, 725 N. Wolfe St., Baltimore, MD 21205-2185. Tel.: 410-955-3827; Fax: 410-614-1944; E-mail: ppederse{at}welchlink.welch.jhu.edu.

  • Received April 29, 1997.
Table of Contents

Submit your work to JBC.

You'll be in good company.